Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Cigna Eyes ESRX, Cycles Suggest It Will Fall

Published 03/08/2018, 11:57 AM
Updated 07/09/2023, 06:31 AM

Cigna (NYSE:CI) dropped 10% and Express Scripts (NASDAQ:ESRX) jumped 11% on Thursday morning.

The price action was driven by Cigna’s planned purchase ESRX for $67 billion in cash and stock. Cigna will also assume $15 billion in ESRX debt. If executed, Cigna shareholders will own 64% of the combined firm, which will lead to expanded offerings and consolidated costs.

Before the deal, our analysis was that ESRX faced considerable risk. Looking at its market cycles, our outlook projected down to $70 for the near-term. The cycles are designated by the black semicircles at the bottom of the chart.
Express Scripts

Our analysis of Cigna also suggested substantial risk, as the declining phase of its current cycle completes. Our target is for a continued drop to $170 in the near term.
Cigna

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.